Massive Bio unveils Reticulum Nexus AI suite for oncology access

By AI, Created 11:51 AM UTC, May 31, 2026, /AGP/ – Massive Bio introduced Reticulum Nexus, a next-generation AI product suite, at ASCO 2026 in Chicago to connect trial matching, physician referrals, patient navigation, and workflow monitoring in one orchestration layer. The company says the system is designed to reduce friction in precision oncology access and move patients more quickly from signal detection to action.

Why it matters: - Reticulum Nexus is designed to replace fragmented trial matching with a closed-loop oncology access workflow. - The suite aims to help patients, physicians, sites, sponsors, advocacy groups, and health systems move faster from identification to enrollment. - Massive Bio is positioning the platform as an AI orchestration layer for precision oncology access, not just a set of point tools.

What happened: - Massive Bio announced the next-generation Reticulum Nexus product suite at ASCO 2026 in Chicago on May 30, 2026. - The suite combines Patient Connect, TrialRelay, NexusPulse, Sentinel Agents, DrArturo AI, and Phoebe AI into a real-time multi-agent ecosystem. - Co-Founder and Chief Medical AI Officer Arturo Loaiza-Bonilla said Reticulum Nexus is designed to help make the next action happen by detecting signals, explaining context, routing referrals, supporting patients, and keeping the journey moving.

The details: - Patient Connect serves as the patient-facing entry point for uploading and sharing medical records, scheduling appointments, receiving trial options, downloading personalized matching reports, and sharing those reports with physicians and loved ones. - Patient Connect also becomes the layer where consent, records, education, engagement, AI-enabled matching, and human navigation begin. - TrialRelay is the physician-facing enrollment orchestration platform built to replace passive referral networks with active handoffs. - TrialRelay uses TrialRouter AI to support physician-to-physician referrals and reduce the chance that patients are lost between identification and enrollment. - TrialRelay integrates DrArturo AI capabilities so physicians can summarize disease details by speech or text, identify matching trials, and refer patients for pre-screening. - NexusPulse Intelligent Calculators turn clinical, biomarker, referral, access, and operational signals into prioritized next actions. - The Trial Opportunity Index estimates whether a patient should be prioritized for trial education, biomarker testing, pre-screening, physician referral, or site activation. - The Biomarker Reassessment Index flags when repeat testing or molecular reassessment may be appropriate. - The Enrollment Friction Score identifies patients at risk of failing to reach enrollment despite potential eligibility. - The Referral Velocity Index measures how quickly referrals move through physicians, sites, coordinators, and sponsor workflows. - The Precision Access Equity Score identifies disparities in trial awareness, biomarker testing, referral completion, geographic access, site activation, and enrollment across underserved communities. - The Progression Urgency Engine identifies when a patient’s window for trial referral, biomarker reassessment, treatment transition, or outreach may be narrowing. - Sentinel Clinical monitors progression signals, treatment transition points, care gaps, missing documentation, biomarker retesting opportunities, and eligibility-relevant changes. - Sentinel Trial tracks trial availability, inclusion and exclusion changes, referral decay, site responsiveness, competing studies, and enrollment bottlenecks. - Sentinel Safety supports adverse event signal extraction, toxicity pattern monitoring, CTCAE-informed workflows, and safety escalation pathways. - Sentinel Equity identifies access disparities, social-needs barriers, underrepresented population gaps, rural access challenges, language barriers, and support-resource needs. - Sentinel Operations tracks workflow delays, missing records, consent gaps, coordinator escalation needs, site communication delays, and unresolved patient journey steps. - DrArturo AI provides longitudinal patient summary generation, trial eligibility and exclusion review, biomarker and line-of-therapy interpretation, guideline-grounded clinical context retrieval, speech- or text-based disease summarization, physician referral support, pre-screening workflow activation, and human-in-the-loop escalation when uncertainty is high. - Phoebe AI helps patients understand where they are, what is needed, and what happens next through education, trial awareness, consent guidance, record collection reminders, multilingual engagement, appointment and referral coordination, social-needs triage, ACS ACTS resource activation, and follow-up. - Massive Bio included a product announcement link for the full Reticulum Nexus suite: the full product announcement.

Between the lines: - Massive Bio is broadening its pitch from trial matching to an operating system for oncology access. - The product names and metrics suggest a push to make AI act on workflow bottlenecks, not just surface recommendations. - The company is emphasizing both clinician support and patient navigation, which signals an attempt to cover the full referral-to-enrollment path.

What’s next: - Massive Bio is likely to use the ASCO launch to drive adoption across providers, sites, and sponsors that need faster trial enrollment workflows. - The company says Reticulum Nexus is built for real-time orchestration, so future updates may focus on expanding automation and signal detection across the oncology journey. - Massive Bio directs readers to its website for more information: More information.